IDEMIA and Altran Team up to Present a New Assisted Driving Car Concept at Paris Motor Show
IDEMIA, the global leader in Augmented Identity, and Altran, the global leader in Engineering and R&D services (ER&D) are teaming up to develop a new user experience based on driverless vehicles interacting with the human environment and with different infrastructures called “Columbia”, a connected, autonomous, and multi-use vehicle integrating Artificial Intelligence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180930005031/en/
(Photo: Business Wire)
IDEMIA technological innovations and solutions, combined with Altran experience and knowhow, aimed at creating two services in one:
- An assisted driving car for personal use based on a shared transport concept
- A transport solution for professional users, including dropping off and collecting items along the route
IDEMIA, with its mastery of leading edge biometric and facial recognition technologies, provides security and enhanced user convenience by creating a strong digital identity. Biometrics ensure reliable data recording when users sign up for the service, and strong authentication of individual vehicle users.
IDEMIA brings different technologies to the concept,
- The e-KYC (know your customer) system is a digital user enrolment pathway that creates an identity,
- A digital car key solution allows the end-user to use a digital key stored in their smartphone to open and start the vehicle. This solution is cloud-based to securely send the digital key to the smartphone, with a secured smartphone environment to store the digital car key and a facial recognition to enable the digital car key,
- The DMS (driving monitoring system) is an on-board camera system that monitors driver behavior and interacts with the driver to return control of the vehicle to the human driver in the event of unforeseen circumstances.
IDEMIA teamed up with Altran to design the vehicle and developed several applications, including:
- Scalable and innovative vehicle platform using more than 20 sensors embedded
- Plug and play Electric Electronic architecture enabling autonomous mobility systems
- System of light interactions for the vehicle, front & rear, with light bands and LED screens
- Intelligent dashboard to interact with the vehicle and services
- Mobile application called “I-ris” enabling user to command the vehicle, send a package and manage shared transport, thanks to IDEMIA facial recognition system, providing secure access to the vehicle
"IDEMIA is proud to be presenting its cutting edge technologies as part of the Colombia project demonstration at the Paris Motor Show. IDEMIA's experience and knowhow guarantee the unique nature of client identities (for both businesses and private individuals) and the reliability of their digital identity. Our priority is guaranteeing convenience and security for users," explains Yves Portalier, Executive Vice-President for Connected Objects at IDEMIA.
"Altran is proud to be working closely with IDEMIA and contribute significantly to the evolution of mobility and resource-sharing with this two-in-one service. This new service allows us to meet the needs of both end-users and B2B players in one combined solution," explains Pascal Brier, Executive Vice-President for Strategy, Technology & Innovation at Altran.
A demonstration of this project will be showcased during Paris Motor Show on the Altran booth #G70 - Hall 7.
OT-Morpho is now IDEMIA, the global leader in Augmented Identity, with the ambition to provide a secure environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect, travel and vote), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, we reinvent the way we think, produce, use and protect this asset, whether for individuals or for objects. We ensure privacy and trust as well as guarantee secure, authenticated and verifiable transactions for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. OT (Oberthur Technologies) and Safran Identity & Security (Morpho) have joined forces to form IDEMIA. With close to $3 billion in revenues and 14,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
Altran ranks as the undisputed global leader in Engineering and R&D services (ER&D), following its acquisition of Aricent. The company offers clients an unmatched value proposition to address their transformation and innovation needs. Altran works alongside its clients, from initial concept through industrialization, to invent the products and services of tomorrow. For over 30 years, the company has provided expertise in aerospace, automotive, defense, energy, finance, life sciences, railway and telecommunications. The Aricent acquisition extends this leadership to semiconductors, digital experience and design innovation. Combined, Altran and Aricent generated revenues of €2.9 billion in 2017, with some 45,000 employees in more than 30 countries. www.altran.com
Follow us on Twitter: @Altran
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors17.6.2019 16:00:00 CEST | Pressemelding
Boehringer Ingelheim and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a first-in-class monoclonal antibody antagonist of SIRPα, being studied in patients with advanced solid tumors. The Phase 1 study is a dose finding study of BI 765063, a myeloid checkpoint inhibitor, administered as a single agent and in combination with Boehringer Ingelheim’s monoclonal antibody PD-1 antagonist BI 754091, a T-lymphocyte checkpoint inhibitor. “We are very pleased with the progress achieved on BI 765063’s program and having the first patient dosed marks a significant milestone in the product’s development. The advancement of a myeloid cell checkpoint blocking monoclonal antibody into the clinic exemplifies Boehringer Ingelheim’s commitment to the next wave of innovation in cancer immunology therapies, with the goal of meaningfully improving outcomes fo
MagicStay Raises €3 Million to Accelerate Its International Development17.6.2019 15:58:00 CEST | Pressemelding
The apartment rental platform dedicated to business travelers, MagicStay.com , announces its full integration into the main business travel booking tools and a €3 million A-series to pursue its development, bringing the amounts raised to more than €8 million since its launch in 2013. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005644/en/ William Lecerf and Valéry Linyer, co-founders of MagicStay (Photo: MagicStay) "This fundraising will allow us to recruit talent to accelerate our growth. We want to sign a quarter of the major French companies and approach one million homes before the end of the year, thanks to the exclusive technologies we now have at our disposal", says Valéry Linÿer, CEO and co-founder, who adds: "We have four main advantages over our competitors: we meet the challenges of duty of care, we are able to customize our tool to meet the constraints of each large company for short and long stays, we ha
EURid Shows a 94% Reduction of Its Footprint since 201217.6.2019 15:32:00 CEST | Pressemelding
EURid, the not-for-profit organisation that operates the .eu and .ею top-level domains, is the first European TLD registry that registered for the EU Eco-Management and Audit Scheme (EMAS) from 2011. Since then, EURid has regularly assessed the environmental impact of its activities and monitored the compliance of its policies and procedures. As over the past four years, in Q2 2019 EURid was audited for the CO2 emissions of the previous year, resulting in an overall footprint of 135 tons CO2eq, which shows a 94% reduction since 2012. “We have achieved carbon neutrality via several actions and the compensation of the audited emissions. We were and are still among the first in our sector to report on our commitment to protect the environment”, commented CEO Marc Van Wesemael. Through EMAS, EURid has had the opportunity to support a multitude of global sustainability initiatives, like the Ugandan Borehole Project, Ecomapuà Project in the Amazon, the Dak Rung Hydropower Project in Vietnam,
Animation, Sound & Vibration – How Visa is Reinforcing Consumer Trust in a Changing Payments World17.6.2019 15:00:00 CEST | Pressemelding
Visa (NYSE: V) today announced global adoption of its sensory branding suite in 25 countries via more than a dozen new partnerships. The suite is comprised of sound, animation and haptic brand cues that occur with a Visa payment transaction. In a digital world increasingly filled with voice-commands, networked appliances and unattended retail environments, Visa’s sensory branding cues offer new ways to enhance the customer experience and convey the trust and security that the Visa brand represents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005240/en/ Visa was the first major payment brand to introduce multi-sensory branding, which included animation, sound and haptic vibration expressions of its brand. After an extensive creation and selection process that involved focus groups and elimination rounds, Visa landed on a single ‘energetic’ and ‘optimistic’ sound, and complementary animation and haptic vibration. Sinc
Study from Project Management Institute Identifies Six AI Technologies Impacting Project Professionals17.6.2019 14:40:00 CEST | Pressemelding
Project Management Institute (PMI) today released its 2019 Pulse of the Profession® In-Depth Report: AI Innovators: Cracking the Code on Project Performance. The report provides an in-depth look at how artificial intelligence (AI) is impacting organizations and the project management profession. Findings reveal that AI disruption is happening and at a large scale: 81 percent of respondents report their organization is being impacted by AI technologies; 37 percent say adopting AI technologies is a high priority for their organization; and project professionals say they expect the proportion of the projects they manage using AI will jump from 23 to 37 percent over the next three years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005558/en/ These insights from a survey of 551 project management practitioners globally show that the presence of AI technologies will continue to grow, requiring shifts in how projects are m
RIBOMIC Announces Positive Top-Line Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet Age-Related Macular Degeneration17.6.2019 13:15:00 CEST | Pressemelding
RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced positive top-line results from its SUSHI study, Phase 1/2a single ascending dose clinical study of RBM-007, anti-FGF2 aptamer, in nine subjects with wet Age-Related Macular Degeneration (wet AMD). SUSHI study achieved the primary endpoint of safety and tolerability, and also demonstrated efficacy trends in favor of RBM-007. Subjects recruited for the SUSHI Study had wet AMD that was poorly responsive to previous intravitreal anti-VEGF therapy. Through the 56-Day exit visit, excluding one uncompleted case in the last cohort, single dose of RBM-007 demonstrated no dose-limiting toxicities, no systemic or ocular serious adverse events. One subject in Cohort 3 showed anterior inflammation, which was resolved after one day of topical prednisolone treatment. Rescue treatment with anti-VEGF therapy was ava